Does the media favor PBYI or CTMX?

In the previous week, CytomX Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.00 beat CytomX Therapeutics' score of 0.05 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PBYI or TRDA?

In the previous week, Puma Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Entrada Therapeutics. Puma Biotechnology's average media sentiment score of 1.00 beat Entrada Therapeutics' score of 0.15 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PBYI or LKFT?

In the previous week, Puma Biotechnology and Puma Biotechnology both had 3 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.19 beat Puma Biotechnology's score of 1.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lakefront Biotherapeutics American Depositary Shares 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VIR or PBYI?

In the previous week, Vir Biotechnology had 20 more articles in the media than Puma Biotechnology. MarketBeat recorded 23 mentions for Vir Biotechnology and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.00 beat Vir Biotechnology's score of 0.26 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Puma Biotechnology (PBYI) Competitors

$10.12 -0.17 (-1.65%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$10.77 +0.65 (+6.40%)

As of 05:07 AM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, LKFT, and VIR

Should you buy Puma Biotechnology stock or one of its competitors? Puma Biotechnology's main competitors and comparable companies include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Lakefront Biotherapeutics American Depositary Shares (LKFT), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Puma Biotechnology compare to ADMA Biologics?

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Puma Biotechnology had 2 more articles in the media than ADMA Biologics. MarketBeat recorded 3 mentions for Puma Biotechnology and 1 mentions for ADMA Biologics. Puma Biotechnology's average media sentiment score of 1.00 beat ADMA Biologics' score of 0.95 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Puma Biotechnology	Positive
ADMA Biologics	Positive

ADMA Biologics has a net margin of 32.98% compared to Puma Biotechnology's net margin of 11.50%. ADMA Biologics' return on equity of 40.17% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
ADMA Biologics	32.98%	40.17%	26.97%

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46
ADMA Biologics	$510.17M	4.53	$146.93M	$0.70	14.73

Puma Biotechnology currently has a consensus target price of $6.00, indicating a potential downside of 40.71%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 81.05%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Puma Biotechnology has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 3.9% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

ADMA Biologics beats Puma Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Puma Biotechnology presently has a consensus target price of $6.00, suggesting a potential downside of 40.71%. CytomX Therapeutics has a consensus target price of $11.90, suggesting a potential upside of 410.73%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46
CytomX Therapeutics	$76.20M	6.66	-$17.37M	-$0.50	N/A

In the previous week, CytomX Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.00 beat CytomX Therapeutics' score of 0.05 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Puma Biotechnology has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Puma Biotechnology has a net margin of 11.50% compared to CytomX Therapeutics' net margin of -435.21%. Puma Biotechnology's return on equity of 20.76% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
CytomX Therapeutics	-435.21%	-38.46%	-30.33%

Summary

Puma Biotechnology and CytomX Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Puma Biotechnology has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

Puma Biotechnology currently has a consensus price target of $6.00, indicating a potential downside of 40.71%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 265.23%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Entrada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Puma Biotechnology had 1 more articles in the media than Entrada Therapeutics. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Entrada Therapeutics. Puma Biotechnology's average media sentiment score of 1.00 beat Entrada Therapeutics' score of 0.15 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46
Entrada Therapeutics	$25.42M	7.44	-$143.75M	-$3.96	N/A

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Puma Biotechnology has a net margin of 11.50% compared to Entrada Therapeutics' net margin of -3,537.73%. Puma Biotechnology's return on equity of 20.76% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Entrada Therapeutics	-3,537.73%	-57.61%	-46.54%

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Puma Biotechnology compare to Lakefront Biotherapeutics American Depositary Shares?

Puma Biotechnology (NASDAQ:PBYI) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Puma Biotechnology has a net margin of 11.50% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Puma Biotechnology currently has a consensus target price of $6.00, indicating a potential downside of 40.71%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $37.00, indicating a potential upside of 27.37%. Given Lakefront Biotherapeutics American Depositary Shares' stronger consensus rating and higher possible upside, analysts plainly believe Lakefront Biotherapeutics American Depositary Shares is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Puma Biotechnology has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Puma Biotechnology. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.52	$363.05M	-$1.41	N/A

In the previous week, Puma Biotechnology and Puma Biotechnology both had 3 articles in the media. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 1.19 beat Puma Biotechnology's score of 1.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Puma Biotechnology beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Vir Biotechnology presently has a consensus price target of $21.86, suggesting a potential upside of 106.01%. Puma Biotechnology has a consensus price target of $6.00, suggesting a potential downside of 40.71%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Vir Biotechnology had 20 more articles in the media than Puma Biotechnology. MarketBeat recorded 23 mentions for Vir Biotechnology and 3 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.00 beat Vir Biotechnology's score of 0.26 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vir Biotechnology has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Puma Biotechnology has a net margin of 11.50% compared to Vir Biotechnology's net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Puma Biotechnology	11.50%	20.76%	13.22%

Puma Biotechnology has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	26.19	-$437.99M	-$1.86	N/A
Puma Biotechnology	$228.40M	2.29	$31.11M	$0.52	19.46

Summary

Puma Biotechnology beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$531.17M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	19.46	10.43	199.17	19.37
Price / Sales	2.29	1,157.81	564.77	81.34
Price / Cash	12.34	118.50	77.16	53.04
Price / Book	3.91	16.93	10.70	6.03
Net Income	$31.11M	-$22.69M	$3.50B	$380.34M
7 Day Performance	3.16%	-4.41%	-2.89%	-2.32%
1 Month Performance	10.72%	-12.46%	-7.36%	-5.29%
1 Year Performance	90.58%	7.64%	3.00%	-2.94%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	1.5522 of 5 stars	$10.12 -1.7%	$6.00 -40.7%	+91.3%	$531.17M	$228.40M	19.46	179
ADMA ADMA Biologics	3.9086 of 5 stars	$10.14 +0.2%	$18.67 +84.2%	-29.1%	$2.27B	$510.17M	14.48	647
CTMX CytomX Therapeutics	2.1589 of 5 stars	$2.56 -1.0%	$11.90 +365.8%	-31.5%	$556.73M	$18.30M	N/A	69	Analyst Forecast
TRDA Entrada Therapeutics	2.4815 of 5 stars	$5.33 -2.7%	$17.75 +232.8%	-16.4%	$207.47M	$25.42M	N/A	152
LKFT Lakefront Biotherapeutics American Depositary Shares	3.0061 of 5 stars	$29.68 +0.6%	$37.00 +24.7%	-14.4%	$1.96B	$990.57M	N/A	1,310	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, LKFT, and VIR

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Puma Biotechnology compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, LKFT, and VIR

How does Puma Biotechnology compare to ADMA Biologics?

Does the media refer more to PBYI or ADMA?

Is PBYI or ADMA more profitable?

Which has better valuation & earnings, PBYI or ADMA?

Do analysts prefer PBYI or ADMA?

Which has more volatility and risk, PBYI or ADMA?

Do institutionals & insiders have more ownership in PBYI or ADMA?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Do analysts rate PBYI or CTMX?

Which has better earnings & valuation, PBYI or CTMX?

Does the media favor PBYI or CTMX?

Which has more risk and volatility, PBYI or CTMX?

Do insiders and institutionals hold more shares of PBYI or CTMX?

Is PBYI or CTMX more profitable?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Which has more risk and volatility, PBYI or TRDA?

Do analysts recommend PBYI or TRDA?

Does the media refer more to PBYI or TRDA?

Which has preferable earnings and valuation, PBYI or TRDA?

Do insiders & institutionals have more ownership in PBYI or TRDA?

Is PBYI or TRDA more profitable?

Summary

How does Puma Biotechnology compare to Lakefront Biotherapeutics American Depositary Shares?

Is PBYI or LKFT more profitable?

Do analysts prefer PBYI or LKFT?

Do insiders and institutionals have more ownership in PBYI or LKFT?

Which has more volatility and risk, PBYI or LKFT?

Which has stronger valuation and earnings, PBYI or LKFT?

Does the media refer more to PBYI or LKFT?

Summary

How does Puma Biotechnology compare to Vir Biotechnology?

Do analysts rate VIR or PBYI?

Does the media prefer VIR or PBYI?

Do institutionals & insiders have more ownership in VIR or PBYI?

Which has more risk and volatility, VIR or PBYI?

Is VIR or PBYI more profitable?

Which has higher valuation and earnings, VIR or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools